Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides an extensive selection of high-quality anti-GHR recombinant antibodies that are expertly designed to achieve outstanding performance. Based on our advanced technology and platforms, we guarantee remarkable specificity, durability, and effectiveness, making these antibodies essential tools for researchers and developers focused on targeted cancer treatment.
The growth hormone receptor (GHR) is a versatile member of the class I cytokine receptor family, influencing various biological processes beyond growth regulation. It plays a significant role in metabolic control, as well as the functioning of vital organs such as the liver, heart, kidneys, intestines, and reproductive system. Notably, GHR signaling impacts aging and cancer development. Excessive GHR activation has been linked to the onset of cancers like colorectal, prostate, and breast cancer. Therefore, targeting GHR offers a promising approach for developing effective cancer therapeutics.
Growth hormone receptor; GHBP; GHIP; GH receptor; growth hormone binding protein; serum binding protein; somatotropin receptor.
This gene encodes a member of the type I cytokine receptor family, which is a transmembrane receptor for growth hormone. The binding of growth hormone to the receptor leads to receptor dimerization and the activation of an intra- and intercellular signal transduction pathway leading to growth. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature. In humans and rabbits, but not rodents, growth hormone binding protein (GHBP) is generated by proteolytic cleavage of the extracellular ligand-binding domain from the mature growth hormone receptor protein. Multiple alternatively spliced transcript variants have been found for this gene.
Creative Biolabs offers a wide range of anti-GHR recombinant antibodies that have been precisely developed to improve research in endocrinology and therapeutic fields. These antibodies feature excellent specificity and affinity for GHR, making them ideal for studying growth hormone signaling pathways and their relevance to illnesses including growth abnormalities, metabolic syndromes, and certain malignancies. In addition, these antibodies are generated through cutting-edge methods, which provide constant quality and repeatability. Our anti-GHR recombinant antibodies are also available in a variety of forms, making them suitable for a wide range of applications like ELISA, Western blotting, immunohistochemistry, and flow cytometry.
Table 1. Featured anti-GHR recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
VS3-FY593 | Recombinant Rabbit Anti-GHR Antibody (clone R02-6E6) | Rat | Rabbit IgG | WB, IP |
ZG-0687J | Rabbit Anti-GHR Recombinant Antibody (clone 10C11) | Human | Rabbit IgG | ELISA, IHC, IF |
NEUT-875CQ | Mouse Anti-GHR Recombinant Antibody (clone CBL068) | Human | Mouse IgG2 | WB, Neut |
NEUT-876CQ | Mouse Anti-GHR Recombinant Antibody (clone CBL584) | Human | Mouse IgG2b | WB, Neut |
TAB-262CQ | Anti-Human GHR Recombinant Antibody (GF185) | Human | Mouse | FC, IP, Inhib |
Creative Biolabs provides a broad selection of recombinant antibodies targeting the Growth Hormone Receptor (GHR), precisely manufactured in our cutting-edge laboratory. Our experienced researchers employ modern methodologies to customize each antibody for maximum accuracy and efficacy in targeting GHR. Through extensive testing and validation processes, we guarantee that our antibodies demonstrate exceptional specificity, robust binding affinity, and advantageous optical characteristics, making them suitable for various research applications.
Fig.1 WB analysis of anti-GHR antibody
(Cat# VS3-FY593, Creative Biolabs).
Fig.2 IHC analysis of anti-GHR antibody
(Cat# ZG-0687J, Creative Biolabs).
Fig.3 IHC analysis of anti-GHR antibody
(Cat# ZG-0687J, Creative Biolabs).
Fig.4 IF analysis of anti-GHR antibody
(Cat# ZG-0687J, Creative Biolabs).
Creative Biolabs offers a reliable range of high-quality anti-GHR antibodies, crafted through advanced genetic technologies to ensure exceptional performance and consistency.
Featured Anti-GHR Recombinant Antibody Production Platforms
Fig.5 Milligram-scale anti-GHR recombinant antibody production.
Fig.6 Gram-scale anti-GHR recombinant antibody production.
Creative Biolabs offers a comprehensive selection of premium anti-GHR recombinant antibodies available in various formats, tailored to satisfy the diverse needs of researchers around the world.
Fig.7 Full-length anti-GHR recombinant antibody production and modalities.
Table 2. Public drug targeting GHR.
Company | Research Phase | Classification | Condition |
OPKO (Originator) Pfizer PROLOR Biotech (OPKO) |
Launched - 2022 |
Fusion Proteins Growth Hormone (GH) Polypeptides, from 41 AA |
Growth hormone deficit Growth hormone secretion disorder |
Sandoz (Originator) | Launched - 2005 |
Biosimilars Follow-on Products Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Growth hormone secretion disorder Prader-Willi syndrome Turner's syndrome |
Children's Mercy Hospitals and Clinics Genentech (Originator) Ipsen Roche (Originator) Sumitomo Pharma |
Launched - 1994 |
Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Anorexia nervosa Crohn's disease Growth failure Growth hormone deficit Obesity Prader-Willi syndrome Turner's syndrome |
BioPartners BioPartners (BioPartners) LG Chem (Originator) LG Life Sciences (LG Chem) |
Launched - 1993 |
Biosimilars Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Growth failure Growth hormone deficit |
Pfizer (Originator) | Launched - 1988 |
Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Growth failure Growth hormone deficit Growth hormone secretion disorder Turner's syndrome |
Amgen (Originator) Ferring JCR (JCR Pharmaceuticals) JCR Pharmaceuticals Savient Pharmaceuticals (Amgen) SciGen Teva |
Launched - 1988 |
Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Dwarfism Growth hormone deficit Turner's syndrome |
Novo Nordisk (Originator) | Launched - 1988 |
Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Growth failure Growth hormone deficit Noonan syndrome Ovulation induction Prader-Willi syndrome Turner's syndrome |
FUJIFILM Merck Serono (Originator) Serono (Merck Serono) Serono (Merck Serono) |
Launched - 1987 |
Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Cachexia Cachexia, AIDS related Congestive heart failure Growth failure Growth hormone deficit Lipodystrophy syndrome Short-bowel syndrome |
Lilly (Originator) | Launched - 1987 |
Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Growth failure Growth hormone deficit Osteogenesis imperfecta Turner's syndrome |
Daewoong (Originator) | Launched |
Growth Hormone (GH) Polypeptides, from 41 AA Recombinant proteins |
Growth hormone deficit |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Whether you are conducting research in the fields of endocrinology, developmental biology, or related areas, our anti-GHR antibodies are designed to provide exceptional performance and reliability. For further information or inquiries regarding our specialized anti-GHR recombinant antibody products, please don't hesitate to reach out to us at your convenience.